# Research Tools for Difficult to Culture Eukaryotic Pathogens (R61/R33 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-ai-23-055-research-tools-for-difficult-to-culture-eukaryotic-pathogens/  
Official notice: https://www.grants.gov/search-results-detail/350038

> National Institutes of Health offered grants of up to $250,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on February 2, 2024.

| Field | Value |
|---|---|
| Opportunity number | RFA-AI-23-055 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | February 2, 2024 |
| Award ceiling | $250,000 |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.855 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## What the grant funds

The purpose of this Notice of Funding Opportunity (NOFO) is to support high risk, milestone-driven approaches for the development of robust culture techniques, and/or genetic and molecular tools to better understand the biology of select human eukaryotic pathogens including the microsporidian Enterocytozoon bieneusi; Pneumocystis jirovecii; Plasmodium vivax; and Babesia microti. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the second phase will depend on the successful completion of milestones.

## Questions people ask

### Is RFA-AI-23-055 still open?

No. It closed on February 2, 2024.

### Who can apply for Research Tools for Difficult to Culture Eukaryotic Pathogens (R61/R33 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Research Tools for Difficult to Culture Eukaryotic Pathogens (R61/R33 Clinical Trial Not Allowed)?

Closed February 2, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $250,000 each.

### Who has been funded under RFA-AI-23-055?

NIH RePORTER lists 8 projects funded under RFA-AI-23-055 in fiscal 2025 to 2026, at 6 institutions. The most were at University of Cincinnati, Tufts University Boston, University of Georgia.

### Who has won Allergy and Infectious Diseases Research grants before?

The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.